New funding round pumps life into Cardioxyl's HNO heart failure candidates
This article was originally published in Scrip
Cardioxyl Pharmaceuticals raised $28 million in a Series B venture funding round to finance development of its second-generation nitroxyl (HNO) donor programs for the treatment of acute and chronic heart failure, but it plans to advance a preclinical asset rather than the therapeutic candidate for which it has completed a Phase IIa clinical trial.
You may also be interested in...
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.
Olema launched this year’s 76th US biopharma IPO. Also, investments in regenerative medicines reached a new high, Qiming closed a $1.2bn China-focused VC fund, D3 Bio led recent venture deals with a $200m round, and Bausch sold $2bn worth of notes to pay down near-term debts.
The $80m financing will support a Phase III myelofibrosis study for the LSD1 inhibitor and earlier-stage programs, but additional late-stage studies will require an initial public offering, likely next year.